What does Virbac do?
Virbac is a dedicated global veterinary pharmaceutical company that develops, manufactures, and distributes a comprehensive portfolio of medicines, vaccines, and diagnostic tools for both companion animals and livestock. Founded by a veterinarian, the company specializes in creating animal health products targeting over fifty species, including specialized treatments for dermatology, dental hygiene, internal and external parasitology, infectious diseases, and nutritional supplements. Operating manufacturing facilities and research laboratories across multiple continents, Virbac supplies veterinary professionals, livestock farmers, and pet owners worldwide with practical solutions designed to prevent, diagnose, and treat various animal pathologies effectively.
Related FAQs
Virbac S.A. operates as a fully public corporate enterprise, with its common shares listed and traded on Euronext Paris.
Virbac SA records strong annual net profit figures scaling past 100 million euros, highlighting its specialized positioning as a dedicated global animal health company.
Financial analyst consensus price targets for SurgePays, Inc. (NASDAQ: SURG) average approximately $3.50, reflecting comprehensive evaluations of its prepaid wireless telecommunications and convenience store point-of-sale platform segments.
Veterinary pharmaceuticals, parasiticides, dermatological topical treatments, and nutritional supplements manufactured by Virbac can occasionally produce adverse reactions in treated companion animals or livestock.
Vista Energy operates as a prominent independent oil and gas exploration and production company focused primarily on developing high-quality unconventional shale oil and gas reserves within Latin America, notably the prolific Vaca Muerta formation in...
Virbac functions entirely as a specialized multinational pharmaceutical company dedicated exclusively to the animal health industry.
Virbac was founded as an independent veterinary pharmaceutical laboratory by veterinarian Max Richter, meaning the company did not undergo a major corporate name change from a prior unrelated commercial identity.
The share price of Virbac SA (traded on Euronext Paris under the ticker VIRP) is approximately 337.50 EUR.
Virbac, a dedicated global animal health pharmaceutical enterprise, manufactures its extensive portfolio of veterinary medicines, vaccines, and pet care products across a specialized network of international production facilities.
Virbac is a dedicated animal health pharmaceutical company utilized globally by veterinarians, livestock producers, and pet owners to prevent, manage, and treat various diseases affecting companion animals and food-producing livestock.
Virbac enjoys a stellar global reputation as a dedicated animal health enterprise focused exclusively on developing, manufacturing, and distributing veterinary pharmaceuticals and vaccines.
Virbac SA shares trade on Euronext Paris under the ticker symbol VIRP at a live market price reflecting the animal health pharmaceutical enterprise's global operational performance.